Carrie Brownstein

924 total citations
32 papers, 699 citations indexed

About

Carrie Brownstein is a scholar working on Oncology, Genetics and Hematology. According to data from OpenAlex, Carrie Brownstein has authored 32 papers receiving a total of 699 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Oncology, 11 papers in Genetics and 11 papers in Hematology. Recurrent topics in Carrie Brownstein's work include Chronic Myeloid Leukemia Treatments (9 papers), Myeloproliferative Neoplasms: Diagnosis and Treatment (9 papers) and CAR-T cell therapy research (5 papers). Carrie Brownstein is often cited by papers focused on Chronic Myeloid Leukemia Treatments (9 papers), Myeloproliferative Neoplasms: Diagnosis and Treatment (9 papers) and CAR-T cell therapy research (5 papers). Carrie Brownstein collaborates with scholars based in United States, United Kingdom and Italy. Carrie Brownstein's co-authors include Andrew T. Jacovina, Domenick J. Falcone, Katherine A. Hajjar, Korsa Khan, Menard M. Gertler, Arunkumar B. Deora, Rebecca Weintraub, Nicolaas Schaap, Suresh S. Ramalingam and Sonja Zweegman and has published in prestigious journals such as Journal of Clinical Oncology, Blood and The Journal of Clinical Endocrinology & Metabolism.

In The Last Decade

Carrie Brownstein

32 papers receiving 678 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Carrie Brownstein United States 12 346 269 174 169 159 32 699
Jesse McGreivy United States 12 335 1.0× 339 1.3× 99 0.6× 185 1.1× 117 0.7× 41 697
Konrad Aumann Germany 16 346 1.0× 220 0.8× 163 0.9× 155 0.9× 138 0.9× 41 731
Unn‐Merete Fagerli Norway 13 286 0.8× 278 1.0× 261 1.5× 138 0.8× 59 0.4× 33 744
A. M. Gianni Italy 15 109 0.3× 294 1.1× 160 0.9× 83 0.5× 95 0.6× 26 619
Frank J. Godinho United States 7 431 1.2× 193 0.7× 296 1.7× 102 0.6× 250 1.6× 12 849
Sarah M. Larson United States 14 180 0.5× 343 1.3× 262 1.5× 200 1.2× 37 0.2× 74 749
Kerry D. Lynch United States 6 352 1.0× 285 1.1× 50 0.3× 74 0.4× 233 1.5× 7 887
Gabriella Sammarelli Italy 16 404 1.2× 438 1.6× 465 2.7× 193 1.1× 109 0.7× 39 938
Christina Kalpadakis Greece 17 156 0.5× 235 0.9× 177 1.0× 311 1.8× 30 0.2× 48 727
Daniela Graziani Italy 11 284 0.8× 393 1.5× 51 0.3× 64 0.4× 107 0.7× 23 767

Countries citing papers authored by Carrie Brownstein

Since Specialization
Citations

This map shows the geographic impact of Carrie Brownstein's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Carrie Brownstein with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Carrie Brownstein more than expected).

Fields of papers citing papers by Carrie Brownstein

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Carrie Brownstein. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Carrie Brownstein. The network helps show where Carrie Brownstein may publish in the future.

Co-authorship network of co-authors of Carrie Brownstein

This figure shows the co-authorship network connecting the top 25 collaborators of Carrie Brownstein. A scholar is included among the top collaborators of Carrie Brownstein based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Carrie Brownstein. Carrie Brownstein is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Sallman, David A., Daniel J. DeAngelo, Naveen Pemmaraju, et al.. (2022). Ameli-01: A Phase I Trial of UCART123v1.2, an Anti-CD123 Allogeneic CAR-T Cell Product, in Adult Patients with Relapsed or Refractory (R/R) CD123+ Acute Myeloid Leukemia (AML). Blood. 140(Supplement 1). 2371–2373. 52 indexed citations
2.
3.
Harrison, Claire, Nicolaas Schaap, Alessandro M. Vannucchi, et al.. (2020). Fedratinib in patients with myelofibrosis previously treated with ruxolitinib: An updated analysis of the JAKARTA2 study using stringent criteria for ruxolitinib failure. American Journal of Hematology. 95(6). 594–603. 104 indexed citations
4.
5.
6.
Harrison, Claire, Nicolaas Schaap, Alessandro M. Vannucchi, et al.. (2019). Fedratinib (FEDR) in myelofibrosis (MF) patients previously treated with ruxolitinib (RUX): A reanalysis of the JAKARTA-2 study.. Journal of Clinical Oncology. 37(15_suppl). 7057–7057. 7 indexed citations
7.
8.
Harrison, Claire, Nicolaas Schaap, Alessandro M. Vannucchi, et al.. (2019). Fedratinib Induces Spleen Responses and Reduces Symptom Burden as First-line or Salvage Therapy in Patients with Myeloproliferative Neoplasm-Associated Intermediate- or High-Risk Myelofibrosis (MF) and Low Platelet Counts. Clinical Lymphoma Myeloma & Leukemia. 19. S355–S355. 6 indexed citations
9.
Harrison, Claire, Nicolaas Schaap, Alessandro M. Vannucchi, et al.. (2019). PS1459 FEDRATINIB IN PATIENTS WITH MYELOPROLIFERATIVE NEOPLASM (MPN)‐ASSOCIATED MYELOFIBROSIS (MF) PREVIOUSLY TREATED WITH RUXOLITINIB (RUX): A REANALYSIS OF THE PHASE 2 JAKARTA‐2 STUDY. HemaSphere. 3(S1). 671–672. 2 indexed citations
10.
Bannerji, Rajat, Jennifer R. Brown, Ranjana H. Advani, et al.. (2016). Phase 1 Study of REGN1979, an Anti-CD20 x Anti-CD3 Bispecific Monoclonal Antibody, in Patients with CD20+ B-Cell Malignancies Previously Treated with CD20-Directed Antibody Therapy. Blood. 128(22). 621–621. 15 indexed citations
11.
Papadopoulos, Kyriakos P., Robin Kate Kelley, Anthony W. Tolcher, et al.. (2015). A Phase I First-in-Human Study of Nesvacumab (REGN910), a Fully Human Anti–Angiopoietin-2 (Ang2) Monoclonal Antibody, in Patients with Advanced Solid Tumors. Clinical Cancer Research. 22(6). 1348–1355. 59 indexed citations
12.
O’Shaughnessy, Joyce, Hartmut Koeppen, Yuanyuan Xiao, et al.. (2015). Patients with Slowly Proliferative Early Breast Cancer Have Low Five-Year Recurrence Rates in a Phase III Adjuvant Trial of Capecitabine. Clinical Cancer Research. 21(19). 4305–4311. 37 indexed citations
13.
Papadopoulos, Kyriakos P., Donna M. Graham, Anthony W. Tolcher, et al.. (2014). A phase 1b study of combined angiogenesis blockade with nesvacumab, a selective monoclonal antibody (MAb) to angiopoietin-2 (Ang2) and ziv-aflibercept in patients with advanced solid malignancies.. Journal of Clinical Oncology. 32(15_suppl). 2522–2522. 4 indexed citations
14.
Kilburn, Lindsay, Mehmet Koçak, Georgina Meneses‐Lorente, et al.. (2013). Phase I trial of capecitabine rapidly disintegrating tablets and concomitant radiation therapy in children with newly diagnosed brainstem gliomas and high-grade gliomas. Neuro-Oncology. 15(6). 759–766. 7 indexed citations
15.
Jimeno, Antonio, Patricia LoRusso, Robert Matthew Strother, et al.. (2013). Phase I study of REGN421 (R)/SAR153192, a fully-human delta-like ligand 4 (Dll4) monoclonal antibody (mAb), in patients with advanced solid tumors.. Journal of Clinical Oncology. 31(15_suppl). 2502–2502. 14 indexed citations
16.
Habben, Kai, Paul Delmar, Carrie Brownstein, et al.. (2011). Investigation of predictive biomarkers for R1507, an anti-IGF1R antibody, in patients with advanced non-small cell lung cancer with progression after first-line chemotherapy.. Journal of Clinical Oncology. 29(15_suppl). 7584–7584. 8 indexed citations
17.
Brownstein, Carrie, et al.. (2006). Diverse pathways mediate chemotherapy-induced cell death in acute lymphoblastic leukemia cell lines. APOPTOSIS. 11(11). 1977–1986. 8 indexed citations
18.
Brownstein, Carrie, Ann Mertens, Pauline Mitby, et al.. (2004). Factors That Affect Final Height and Change in Height Standard Deviation Scores in Survivors of Childhood Cancer Treated with Growth Hormone: A Report from the Childhood Cancer Survivor Study. The Journal of Clinical Endocrinology & Metabolism. 89(9). 4422–4427. 43 indexed citations
19.
Brownstein, Carrie, Arunkumar B. Deora, Andrew T. Jacovina, et al.. (2003). Annexin II mediates plasminogen-dependent matrix invasion by human monocytes: enhanced expression by macrophages. Blood. 103(1). 317–324. 98 indexed citations
20.
Brownstein, Carrie, Domenick J. Falcone, Andrew T. Jacovina, & Katherine A. Hajjar. (2001). Annexin II. Annals of the New York Academy of Sciences. 947(1). 143–156. 29 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Jesse McGreivy Breakdown of academic impact, for papers by Konrad Aumann Breakdown of academic impact, for papers by Unn‐Merete Fagerli Breakdown of academic impact, for papers by A. M. Gianni Breakdown of academic impact, for papers by Frank J. Godinho Breakdown of academic impact, for papers by Sarah M. Larson Breakdown of academic impact, for papers by Kerry D. Lynch Breakdown of academic impact, for papers by Gabriella Sammarelli Breakdown of academic impact, for papers by Christina Kalpadakis Breakdown of academic impact, for papers by Daniela Graziani
Rankless by CCL
2026